Diabetic Neuropathy – Epidemiology – Asia-Pacific
Clarivate Epidemiology’s coverage of diabetic neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of diabetic neuropathy for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s diabetic neuropathy forecast will answer the following questions:
- Of all people with diabetic neuropathy, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with diabetic neuropathy, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of diabetic neuropathy over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology forecasts one diabetic neuropathy patient population:
- Total prevalent cases of diabetic neuropathy.
Note: Coverage may vary by country.
